Edwards Lifesciences Reports Tomorrow With Street Penciling In the Same Growth It's Seen All Year

Edwards Lifesciences Corp (EW) reports second-quarter 2026 earnings after the close on July 23, 2026, with analysts expecting $0.73 per share—a significant acceleration from the prior year's $0.67. With the stock trading below most short-term moving averages and analyst sentiment weakening sharply in recent weeks, investors will be watching whether the medical device maker can deliver another beat and restore momentum to shares that have pulled back from recent highs.

Part 1: Earnings Preview

Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring, with key franchises in transcatheter aortic valve replacement (TAVR), surgical heart valves, and hemodynamic monitoring systems. The company serves hospitals and healthcare providers worldwide with technologies designed to treat advanced cardiovascular disease.

Edwards reports Q2 2026 results after the close on July 23, with the Street expecting $0.73 per share on 9 analyst estimates ranging from $0.72 to $0.75. The company most recently reported $0.78 per share for Q1 2026, beating estimates by 4.00%. The current consensus represents +8.96% growth versus the $0.67 reported in the year-ago quarter, reflecting expectations for continued momentum in the company's core TAVR franchise and international expansion.

Three key themes define this earnings story: TAVR Market Penetration and Competitive Dynamics—investors will scrutinize procedure volumes and market share trends as Edwards navigates an increasingly competitive transcatheter valve landscape, particularly in international markets where adoption is accelerating. Gross Margin Trajectory—with manufacturing scale and product mix evolution, the Street is focused on whether Edwards can sustain margin expansion while investing in next-generation platforms. 2026 Guidance Cadence—after raising full-year EPS estimates from $2.56 to $3.00, management's commentary on second-half visibility and procedure growth assumptions will be critical for validating the elevated outlook.

Analyst commentary ahead of the release emphasizes cautious optimism. The consensus has been revised upward significantly, with full-year 2026 estimates climbing from $2.56 to $3.00, suggesting growing confidence in the company's ability to execute. However, recent technical weakness and a sharp deterioration in Barchart's Opinion signal from 88% Buy a month ago to just 40% Buy currently indicate some near-term caution among market participants despite the constructive fundamental backdrop.

Part 2: Historical Earnings Performance

Edwards Lifesciences has demonstrated a strong track record of exceeding expectations, beating consensus estimates in three of the past four quarters. The company delivered its largest surprise in Q3 2025 with a +13.56% beat ($0.67 actual vs. $0.59 estimate), followed by another solid outperformance in Q2 2025 at +8.06% ($0.67 vs. $0.62). The most recent quarter, Q1 2026, produced a +4.00% beat ($0.78 vs. $0.75), maintaining the positive momentum.

The lone miss came in Q4 2025, when Edwards reported $0.58 versus the $0.62 estimate, a -6.45% shortfall that briefly interrupted an otherwise consistent pattern of outperformance. However, the company quickly returned to form the following quarter, suggesting the Q4 miss was an anomaly rather than a trend reversal. The pattern indicates Edwards typically delivers 4–14% upside to Street estimates, with the magnitude of beats appearing to moderate slightly in recent quarters as analysts have adjusted their models higher.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Edwards Lifesciences reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Edwards exhibits highly volatile post-earnings price action, with an average absolute Day +1 move of 7.70%—nearly ten times the typical Day 0 move of 0.74%. The most dramatic reaction came after Q2 2024 results (July 24, 2024), when shares plunged -31.34% the following session despite minimal Day 0 movement, suggesting a severe guidance disappointment or fundamental concern that emerged after the close.

Excluding that outlier, Edwards typically sees strong positive momentum following earnings, with five of the past eight Day +1 sessions producing gains averaging over 5%. The most recent report in April 2026 followed this pattern: a modest -2.22% decline on Day 0 reversed into a +5.56% rally on Day +1 as investors digested the beat and guidance. The average Day +1 range of 5.68% indicates substantial intraday volatility regardless of direction, creating both risk and opportunity for traders around the event.

Part 2.2: Options Market Expected Move

The options market is pricing a 7.77% expected move for the August expiration (30 days out, encompassing this earnings event), which sits slightly above the historical average Day +1 move of 7.70% but well below the average Day +1 range of 5.68% when considering intraday volatility. This suggests options traders are anticipating a significant reaction consistent with Edwards' recent history, though not pricing in another extreme outlier like the July 2024 event.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on Edwards Lifesciences, with the consensus at 4.38 out of 5.00—firmly in Buy territory. The rating breakdown shows 19 Strong Buys, 2 Moderate Buys, and 8 Holds, with zero sell ratings among the 29 analysts covering the stock. This distribution reflects broad confidence in the company's structural growth drivers and market leadership position.

Sentiment has remained unchanged over the past month, with the rating composition holding steady at 19 Strong Buys, 2 Moderate Buys, and 8 Holds. The stability suggests analysts are comfortable with their current views heading into the Q2 report, having already incorporated recent business trends into their models.

The average price target of $99.74 implies 18.2% upside from the current price of $84.37, with the range spanning from $81.00 to $110.00. The wide target spread reflects differing views on the pace of TAVR market expansion and Edwards' ability to defend margins in a competitive environment, but even the low-end target sits near current levels, indicating limited downside risk in the analyst community's view.

Part 4: Technical Picture

Edwards Lifesciences enters earnings with a deteriorating technical setup that has weakened significantly in recent weeks. The Barchart Technical Opinion currently stands at 40% Buy, down sharply from 80% Buy one week ago and 88% Buy one month ago—a dramatic reversal that signals growing near-term pressure on the stock.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum has stalled after the recent pullback
• Medium-term (50% Buy): Neutral-to-positive reading indicates the intermediate trend remains constructive despite recent weakness
• Long-term (50% Buy): Moderate buy signal reflects a still-intact longer-term uptrend, though momentum has clearly faded

Trend Characteristics: The trend is characterized as Soft in strength and Weakest in direction, indicating a vulnerable technical environment heading into the earnings event with limited momentum support.

The stock is trading at $84.37, positioned below the 5-day ($85.50), 10-day ($88.02), 20-day ($90.10), and 50-day ($87.06) moving averages, confirming the recent downward pressure. However, the price remains above both the 100-day ($84.58) and 200-day ($83.36) moving averages, suggesting longer-term support is nearby and the pullback has brought shares back toward key technical floors.

The current price of $84.37 sits just above the 100-day moving average at $84.58, a critical support level that has contained the recent decline. A break below this level could trigger further technical selling toward the 200-day average at $83.36, while a strong earnings beat could propel shares back above the 50-day average at $87.06 and retest the 20-day at $90.10. The overall setup is cautionary heading into the report—while longer-term support remains intact, the sharp deterioration in short-term momentum and the stock's position below all near-term moving averages suggests limited technical cushion if results or guidance disappoint.